KNCV Knowledge Institute

The KNCV Knowledge Institute brings together the research and innovation expertise within our network. The Knowledge Institute aims to showcase our track record in research and innovation related to TB-associated health issues, and health systems.

KNCV Knowledge Institute objectives

The KNCV Knowledge Institute objectives are:

  1. To ensure that KNCV-supported innovations are at the forefront of research and development in the field, with a focus on quality assurance. Any innovations that prove to be effective will be effectively communicated and widely applied across KNCV-supported countries and beyond. This will facilitate national, regional, or global scale, as appropriate.
  2. To formalize relationships with universities and training institutes, to ensure that they are mutually beneficial and promote clear knowledge transfer. This involves consolidating and structuring the KNCV internship and exchange program. This will enhance KNCV’s expertise in TB and related health issues and support the development of future leaders in the field.

To establish KNCV as a reference centre for TB research, innovation, and project implementation, we are undertaking a systematic effort to raise awareness of our existing resources.

 

KNCV Knowledge Institute expected outcomes by 2025:

  • KNCV-supported research and innovations are easily accessible and visible on the KNCV websites worldwide and in KNCV communications
  • KNCV research network mapped, clearly displayed on KNCV websites worldwide and up to date
  • KNCV alumni network formed and engaged for dissemination and feedback
  • KNCV Knowledge Institute newsletter published at least twice a year and disseminated across KNCV worldwide, the KNCV research network and partners
  • All study protocols are reviewed by the KNCV ERB
  • The proceedings of KNCV ERB meetings are systematically documented
  • A social scientist involved in all qualitative research at KNCV 

 

More information

Read more about our Ethical Review Board (ERB), our Experts and our Publications.

Read more

  • 12/01/2020

    TB Stigma Reduction Symposium

    INVITATION: Stigma and discrimination are recognized as some of the most commonly identified barriers to fight the Tuberculosis (TB) epidemic.

    Lees meer
  • 12/01/2020

    The story of Abdurahim

    Four-year-old Abdurahim from Kyrgyzstan is so small he looks half that age. He had spinal and intra-thoracic lymph node tuberculosis…

    Lees meer
  • 12/12/2019

    Start of a new era in fight against drug resistant TB

    WHO released a rapid communication on the treatment of drug resistant (DR) and extensively drug resistant (XDR) tuberculosis (TB). This…

    Lees meer
  • 20/11/2019

    7th European Advanced Course in Clinical Tuberculosis

    The 7th European Advanced Course in Clinical Tuberculosis (TB) offered an informative and interactive program with national and international speakers…

    Lees meer
  • 31/10/2019

    3HP regimen soon to be accessible in Malawi

    KNCV Tuberculosis Foundation Malawi welcomes the substantial reduction in the price of the anti-tuberculosis drug rifapentine, announced today at the…

    Lees meer
  • 31/10/2019

    Important price reduction improves access to TB prevention

    KNCV Tuberculosis Foundation welcomes the announcement of a substantial reduction in the price of an anti-tuberculosis medicine through the support…

    Lees meer
  • 25/09/2019

    Innovative TB treatment support project kicks off in the Philippines

    ASCENT aims to assist patients succeed in treatment using digital adherence technology. On World Lung Day, the innovative TB treatment…

    Lees meer
  • 01/09/2019

    Antacid helps tuberculosis bacteria to survive

    In 2017, some 10 million people suffered from tuberculosis and 1.6 million died of the disease. One reason why infection…

    Lees meer
  • Current recommended treatment regimen for highly drug-resistant TB (left) versus the BPaL regimen (right).

    14/08/2019

    FDA approval of BPaL regimen an important breakthrough in TB control

    The US Food & Drug Administration (FDA) today approved pretomanid for the treatment of highly drug-resistant forms of tuberculosis (TB)…

    Lees meer
  • 23/07/2019

    ASCENT: Empowering patients through digital technology

    GENEVA/THE HAGUE, The next three and a half years, KNCV Tuberculosis Foundation will lead the innovative ASCENT project, which stands…

    Lees meer
  • 20/06/2019

    Call to Action for awareness on AMR

    KNCV Tuberculosis Foundation is one of the civil society organizations that signs the Call to Action for awareness on antimicrobial…

    Lees meer
  • 28/05/2019

    Wolfheze Workshops 2019: inspiring knowledge exchange & concrete steps forward

    KNCV Tuberculosis Foundations can look back at an inspiring edition of the Wolfheze Workshops 2019 (15-17…

    Lees meer
  • 15/05/2019

    Unique gathering of TB and HIV experts in Scheveningen

    Biennial Wolfheze Workshops focuses on alarming tandem of infectious diseases THE HAGUE, 15 May 2019 International experts in the field…

    Lees meer
  • 12/04/2019

    Dutch civil society calls upon increase of Dutch commitment to the Global Fund

    The Hague – This week, KNCV Tuberculosis Foundation, in cooperation with Aidsfonds and nine other Dutch civil society organisations* called…

    Lees meer
  • 24/03/2019

    IT’S TIME … for new TB drugs and treatment regimens for all

    THE HAGUE – Today, on World TB Day, the international TB community raises awareness about the deadliest infectious disease in…

    Lees meer

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.